Genetic testing for colon cancer is evolving far beyond a single marker, with researchers identifying multiple DNA mutations that can predict which patients will respond to specific treatments and which face worse outcomes. While KRAS testing received major clinical backing in early 2026, oncologists now recognize that other genetic polymorphisms, including BRAF mutations and 18q deletions, offer crucial insights into personalized treatment planning for colorectal cancer patients.

What Genetic Markers Tell Us About Colon Cancer Outcomes?

For years, doctors relied on tumor stage alone to guide colon cancer treatment decisions. But emerging research shows that the genetic makeup of a tumor reveals far more about how a patient will respond to therapy. The American Society of Clinical Oncology (ASCO) issued a provisional clinical statement in January 2026 supporting routine KRAS testing in patients with metastatic colon cancer before treatment begins.

However, KRAS is just the beginning. Researchers presented findings at the 2009 Gastrointestinal Cancers Symposium showing that colon cancer treatment is heading in the same direction as breast cancer, where multiple genetic signatures guide therapy selection. The goal is to move toward the kind of personalized medicine that has transformed breast cancer care, where doctors can predict which patients need aggressive chemotherapy and which can safely avoid it.

"Can we do the same in colorectal cancer? Would this help determine which stage II patients need chemotherapy? Not only would this optimize patient care but it would help us afford care in an era of escalating costs," said Dr. Alan P. Venook, professor of clinical medicine at the University of California, San Francisco.

Dr. Alan P. Venook, Professor of Clinical Medicine, University of California, San Francisco

Which Genetic Mutations Matter Most for Treatment Response?

Several genetic markers have emerged as powerful predictors of how colon cancer will behave and respond to therapy:

• KRAS mutations: Found in approximately 30% or more of colorectal tumors, KRAS mutations predict whether patients will respond to EGFR-targeted antibody drugs like cetuximab and panitumumab. Patients with wild-type (normal) KRAS respond to these drugs, while those with mutated KRAS do not.
• BRAF mutations: This gene mutation appears to be prognostic, meaning it predicts survival outcomes independent of treatment choice. Patients with BRAF V600E mutations had significantly worse outcomes across multiple treatment regimens, with median progression-free survival of just 3.5 to 5 months compared to 12 to 12.8 months in patients with normal BRAF.
• 18q deletions: Researchers discovered 15 years ago that stage II colon cancer patients with deletions in the 18q chromosome behaved like stage III patients, while those with intact 18q almost never died from their disease. This marker is now being tested in a clinical trial called ECOG 5202 involving 3,125 patients.

The implications are significant. In one study of 168 patients with metastatic colorectal cancer, researchers found that KRAS mutations were present in 37% of tumors, BRAF mutations in 8%, and PIK3CA mutations in 15%. When patients with BRAF mutations received oxaliplatin-based chemotherapy, their median progression-free survival was just 5 months compared to nearly 12 months for those with normal BRAF. Similar disparities appeared with irinotecan-based regimens and bevacizumab-containing treatments.

"BRAF mutation in the primary tumor identifies patients who carry an especially poor prognosis, regardless of the specific treatment regimen. If our conclusions are independently confirmed, patients with BRAF V600E mutation might be justified in foregoing approved treatments in favor of investigational therapy," reported Dr. John Sougklakos, of University Hospital, Heraklion, Greece.

Dr. John Sougklakos, University Hospital, Heraklion, Greece

How Are Doctors Using This Information to Personalize Treatment?

The shift toward genetic-guided treatment is already underway in clinical practice. The CALGB/SWOG 80405 trial, led by Dr. Venook, was amended to exclude patients with mutated KRAS from receiving EGFR antibodies, since data showed these patients would not benefit from the drugs. Future trials are expected to follow this approach, using genetic testing to match patients with therapies most likely to work for their specific tumor.

Beyond tumor genetics, researchers are also examining the patient's own genetic makeup, a field called pharmacogenetics. Certain transporter genes affect how quickly the body clears chemotherapy drugs like oxaliplatin and irinotecan, influencing both treatment effectiveness and side effects. In the CALGB 80203 trial, benefit from oxaliplatin could be predicted based on specific transporter genes, though the most predictive gene variant was rare, appearing in only four study participants.

Testing for BRAF mutations should become available for routine clinical use within approximately two years, according to Dr. Venook. This timeline suggests that within the next 24 months, oncologists will be able to order BRAF testing as part of standard pretreatment evaluation for colon cancer patients, similar to how KRAS testing is now routine.

Dr. Venook

What Does This Mean for Colon Cancer Patients?

The expansion of genetic testing in colorectal cancer represents a fundamental shift in how doctors approach treatment planning. Rather than using a one-size-fits-all approach based on cancer stage, physicians can now tailor therapy based on the specific genetic characteristics of each patient's tumor. This personalized approach aims to maximize treatment effectiveness while minimizing unnecessary chemotherapy exposure for patients unlikely to benefit.

For patients with stage II colon cancer, genetic markers like 18q deletion status may soon determine whether chemotherapy is necessary at all. For those with metastatic disease, KRAS and BRAF testing can guide selection of targeted antibody therapies versus chemotherapy combinations. Patients with BRAF mutations, who face particularly poor outcomes with standard treatments, may be candidates for investigational therapies not yet widely available.

"Clearly, this is all just scratching the surface, and many other genetic polymorphisms or markers promise to be identified and incorporated into treatment planning," concluded Dr. Venook.

Dr. Alan P. Venook, Professor of Clinical Medicine, University of California, San Francisco

The field is moving rapidly, with researchers evaluating additional genetic markers that may predict response to bevacizumab (a drug targeting blood vessel growth) and other newer therapies. As testing becomes more accessible and affordable, genetic profiling is expected to become standard practice for all colon cancer patients, not just those with advanced disease.